BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $13,226,292 | -2.2% | 1,152,116 | +7.4% | 0.00% | -25.0% |
| Q3 2022 | $13,521,262 | -35.6% | 1,073,116 | -45.9% | 0.00% | -20.0% |
| Q2 2022 | $21,005,162 | +62.4% | 1,985,365 | +149.6% | 0.01% | +66.7% |
| Q1 2022 | $12,935,285 | +30.1% | 795,528 | +10.8% | 0.00% | +50.0% |
| Q4 2021 | $9,940,000 | -13.2% | 717,674 | -9.9% | 0.00% | -33.3% |
| Q3 2021 | $11,448,000 | +322.6% | 796,674 | +364.9% | 0.00% | +200.0% |
| Q2 2021 | $2,709,000 | +55.4% | 171,351 | 0.0% | 0.00% | – |
| Q1 2021 | $1,743,000 | -33.3% | 171,351 | -51.1% | 0.00% | -100.0% |
| Q4 2020 | $2,613,000 | -26.3% | 350,760 | -66.0% | 0.00% | 0.0% |
| Q3 2020 | $3,545,000 | +36.9% | 1,032,093 | +89.9% | 0.00% | 0.0% |
| Q2 2020 | $2,590,000 | – | 543,493 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |